# Pizarra — PT-pseudo_25007bb807d7 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_25007bb807d7
Task: 1

Encounter: Urology - outpatient on 19 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 17.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.462 ng/mL²
  - PSA velocity: 1.29 ng/mL/yr
  - Prior PSA: 16.1 ng/mL
  - Prostate volume: 36.82 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.85766834 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.

Vitals: weight 83 kg, height 193 cm, BMI 22.3, BP 122/68 mmHg, HR 74 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2015).

Chief complaint: Persistent prostate-specific antigen elevation prompted mpMRI scheduling.

History: A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications.

Physical examination: DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly.

Patient info: office administrator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 11 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024).
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.88 +/- 0.11   (95% CI 0.60-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.04  (few labelled cases resemble this one)
  - 8.0 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=17.0, age=61.0, psad=0.462, dre_ord=0.0, vol=36.82, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the specific PSA velocity (1.29 ng/mL/yr) or the full PSA history trend, which is critical given the high PSA level (17.0 ng/mL) and the PI-RADS 5. It also missed the context provided by the full mpMRI report and the laboratory panel, which might contain crucial information regarding the aggressiveness or extent of the lesion that influences the biopsy decision.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.88), but the high csPCa predicted probability (0.85766834) combined with a normal DRE might be contradictory. Furthermore, the prior does not account for the PSA velocity (1.29 ng/mL/yr), which indicates rapid progression, potentially overriding the PI-RADS 5 score if the clinical context suggests a lower risk profile for biopsy. The wide confidence interval (0.60-1.00) suggests high uncertainty, meaning the prior's strong suggestion might be based on insufficient data.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> -> radiology / mpMRI report -> If the report details suggest a very low-risk lesion despite PI-RADS 5, it would decrease the likelihood of biopsy.
  <document> -> PSA history (trend) -> If the trend is flat or decreasing despite the high current PSA, it would reduce the urgency for biopsy.
  <document> -> laboratory results (full panel) -> If the lab panel shows markers suggesting benign prostatic hyperplasia (BPH) or other conditions, it would temper the biopsy recommendation.
  <document> -> previous GP / urology consultation notes -> These notes might contain context regarding the initial presentation or any prior discussions about surveillance.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_25007bb807d7", "radiology_report": "Subject: mpMRI Prostate\nDate: 15 January 2025\nFacility: Amsterdam UMC (VUmc location)\n\nClinical indication: Evaluation of elevated PSA (17.0 ng/mL) and clinical suspicion of malignancy.\n\nFINDINGS: The gland measures 36.82 mL in total volume. T2-weighted sequences highlight a distinct, 18 mm hypointense focus within the right peripheral zone, spanning the base to mid-gland. Diffusion-weighted imaging reveals pronounced restriction with corresponding ADC hypointensity. Dynamic contrast-enhanced phases demonstrate early, focal arterial enhancement localized to the lesion. There is no evidence of extraprostatic extension, seminal vesicle invasion, or pelvic lymphadenopathy.\n\nIMPRESSION: PI-RADS 5 lesion in the right peripheral zone. Prostate volume 36.82 mL yielding a PSA density of 0.462 ng/mL/mL. csPCa predicted probability 0.85766834"}

  **PSA history**
  {"case_id": "PT-pseudo_25007bb807d7", "psa_trend": [{"date": "Jun 2022", "val": 5.7}, {"date": "Jan 2023", "val": 11.3}, {"date": "Sep 2023", "val": 15.4}, {"date": "May 2024", "val": 3.1}, {"date": "Jan 2025", "val": 17.0}]}

  **laboratory results**
  {"case_id": "PT-pseudo_25007bb807d7", "laboratory_results": [{"name": "PSA", "val": "17.0 ng/mL", "date": "05 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.60 ng/mL", "date": "05 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "05 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "15.7 g/dL", "date": "05 Dec 2024", "flag": ""}, {"name": "WBC", "val": "7.9 x10^9/L", "date": "05 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "224 x10^9/L", "date": "05 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "91 umol/L", "date": "05 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "05 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "15.4 nmol/L", "date": "05 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "66 U/L", "date": "05 Dec 2024", "flag": ""}, {"name": "LDH", "val": "128 U/L", "date": "05 Dec 2024", "flag": ""}]}

  **previous GP / urology consultation notes**
  {"case_id": "PT-pseudo_25007bb807d7", "previous_notes": [{"date": "21 Sep 2024", "author": "Dr. R. van den Berg (GP)", "text": "The patient was reviewed following a PSA reading of 16.1 ng/mL in May 2024. Symptoms remain minimal with an IPSS score of four, and cross-sectional imaging was arranged to clarify the aetiology of the persistent elevation. A routine urinalysis was unremarkable ahead of the planned urology visit."}, {"date": "25 Jan 2024", "author": "Dr. R. van den Berg (GP)", "text": "Follow-up consultation regarding a PSA of 15.3 ng/mL obtained in September 2023. The gentleman reports only mild voiding frequency without nocturia or urgency, and a repeat PSA was arranged to monitor the trajectory."}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - mpMRI report: PI-RADS 5 lesion in the right peripheral zone with diffusion restriction and arterial enhancement.
  - PSA history: PSA velocity of 1.29 ng/mL/yr, indicating rapid progression.
  - Laboratory results: High PSA (17.0 ng/mL) and a low %Free PSA (21%).

  AGAINST sampling this patient now:
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
  - Previous notes: Patient reports minimal LUTS (IPSS score of 4/35) and no other concerning symptoms.

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which aligns with the statistical prior but is supported by specific pathological imaging data.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging and concerning biochemical data. The PI-RADS 5 lesion in the right peripheral zone is a decisive factor, which is further supported by a high PSA velocity of 1.29 ng/mL/yr. The statistical prior suggested biopsy, and the evidence confirms that the high-risk MRI finding and rapid PSA progression mandate further tissue sampling.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
